5-Amino-1MQ
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
We have not published an audit on 5-Amino-1MQ. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
It works by blocking an enzyme called NNMT (nicotinamide N-methyltransferase), which, when elevated in fat tissue, depletes vitamin B3 necessary for NAD+ production. By inhibiting NNMT, it preserves B3, increases NAD+, and promotes fat cells to function more like lean tissue. [Source: Peptide Dosing Protocols]
5-Amino-1MQ blocks an enzyme called NNMT that wastes vitamin B3 in fat tissue, which raises cellular energy (NAD+) and causes fat cells to behave more like lean tissue, without suppressing appetite.
Reported side effects
The most commonly reported side effects are mild warmth and a slight heart-rate increase in the first couple of weeks, insomnia when dosed too late in the day, and mild stomach upset with oral capsules.
Who should avoid it
People who are pregnant or breastfeeding, have a cancer history, liver disease, are children or teenagers, take certain methyl-donor-sensitive medications, or have known sleep disorders should avoid 5-Amino-1MQ.
What gets monitored
Baseline ALT/AST check and recheck during long cycles. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for 5-Amino-1MQ or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 100 mg once daily · Low: 50 mg once daily · High: 150 mg once daily | once daily8 to 12 weeks on, 4 to 6 weeks off · 8 to 12 weeks on, 4 to 6 weeks off | oral | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: 4 to 7 hours. The most common research community target dose is 100 mg once daily. |
- once daily8 to 12 weeks on, 4 to 6 weeks off · 8 to 12 weeks on, 4 to 6 weeks off
- oral
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: 4 to 7 hours. The most common research community target dose is 100 mg once daily.
- Reconstitute each vial with 3.0 mL bacteriostatic (BAC) water for ~16.7 mg/mL; 2 vials = ~6 mL total. (Subcutaneous form; the compound is also taken orally.)
Common questions
What is 5-Amino-1MQ?
5-Amino-1MQ is short for 5-amino-1-methylquinolinium, a small synthetic molecule that blocks an enzyme called NNMT.
Is 5-Amino-1MQ a peptide?
No, it is a small molecule, not a chain of amino acids.
Is 5-Amino-1MQ FDA-approved?
No, it has no FDA-approved use as of June 2026.
How much 5-Amino-1MQ do people take?
The typical range is 50 to 150 mg per day, usually starting at 50 mg.
What is the injection dose for 5-Amino-1MQ?
The subcutaneous range is 2.5 to 5 mg per day.
Oral capsule or subcutaneous injection — which is better?
Oral is the standard due to better absorption.
What are the main side effects?
Common side effects include mild stimulant-like effects, insomnia, and mild stomach upset.
Who should avoid 5-Amino-1MQ?
Pregnant or breastfeeding individuals, those with active cancer, liver disease, children, and those with sleep disorders should avoid it.
Sources
- 01Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology (2018)
- 02Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. PubMed (peer-reviewed) (2024)
- 03Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature (2014)
- 04Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and lean-diet substitution reduces body weight and liver fat in obese mice. Scientific Reports (2021)
- 05Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates muscle stem cells and progenitor cell function. Biochemical Pharmacology (2019)
- 06Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends in Endocrinology and Metabolism (2017)
- 07National Center for Biotechnology Information. PubChem Compound Summary for 5-Amino-1-methylquinolinium (5-Amino-1MQ). PubChem (2026)
- 08U.S. Food and Drug Administration. Drugs@FDA: search confirms no approved 5-Amino-1MQ product as of June 2026. FDA.gov (2026)
- 09ClinicalTrials.gov. Search results for 5-Amino-1MQ and NNMT inhibitor (no active human trials registered as of June 2026). ClinicalTrials.gov (2026)
The reference sections above are imported from our compound knowledge base, which classes the evidence for 5-Amino-1MQ as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
AOD9604 is a modified C-terminal fragment of human growth hormone (residues 176-191), studied in lipid metabolism research models.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.
Peptide bioregulator referenced for pineal support.